Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors

• Autorzy: Jazowiecka-Rakus J. , Jarosz M. , Kozlowska D. , Sochanik A. , Szala S.
• Języki publikacji: EN

Abstrakty

EN

Growth of tumors is strongly dependent upon supply of nutrients and oxygen by de novo formed blood vessels. Inhibiting angiogenesis suppresses growth of primary tumors as well and affects development of metastases. We demonstrate that recombinant MBP/vasostatin fusion protein inhibits proliferation of endothelial cells in vitro. The therapeutic usefulness of such intratumorally delivered recombinant protein was then assessed by investigating its ability to inhibit growth of experimental murine melanomas. In the model of B16-F10 melanoma the MBP/vasostatin construct significantly delayed tumor growth and prolonged survival of treated mice. A combination therapy involving MBP/vasostatin construct and cyclophosphamide was even more effective and led to further inhibition of the tumor growth and extended survival. We show that such combination might be useful in the clinical setting, especially to treat tumors which have already formed microvessel networks.

Słowa kluczowe

EN

cyclophosphamide; therapy; melanoma tumour; vasostatin; murine melanoma; tumour growth; combination therapy; melanoma

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2007
• Tom: 54
• Numer: 1
• Opis fizyczny: p.125-133,fig.,ref.

Twórcy

autor

Jazowiecka-Rakus J.

• Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland

autor

Jarosz M.

autor

Kozlowska D.

autor

Sochanik A.

autor

Szala S.

Bibliografia

• Atreya CD, Singh NK, Nakhasi HL (1995) The Rubella virus RNA binding activity of human calreticulin is localized to the N-terminal domain. J Virol 69: 3848–3851.
• Brooks PC, Silletti S, Schalscha TL, Friedlander M, Cheresh DA (1998) Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92: 391–400.
• Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878–1886.
• Burke PA, DeNardo SJ (2001) Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Oncol Hematol 39: 155–171.
• Cao Y (2004) Antiangiogenic cancer therapy. Semin Cancer Biol 14: 139–145.
• Chen Q-R, Kumar D, Stass SA, Mixson J (1999) Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 59: 3308–3312.
• Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186.
• Folkman J (2000) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15–18.
• Folkman J (2003) Fundamental concepts of the angiogenic process. Curr Mol Med 3: 643–651.
• Gupta SK, Hassel T, Singh JP (1995) A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA 92: 7799–7803.
• Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, Kalluri R (2004) Thrombospondin- 1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64: 1570–1574.
• Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364.
• Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58–62.
• Jazowiecka-Rakus J, Jarosz M, Szala S (2006) Combination of vasostatin gene therapy with cyclophosphamide inhibits growth of B16(F10) melanoma tumors. Acta Biochim Polon 53: 199–202.
• Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R (2000) Canstatin, a novel martix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2: 1209–1215.
• Kerbel RS, Kamen B (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423–436.
• Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15–R24.
• Loeffler M, Kruger JA, Reisfeld RA (2005) Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res 65: 5027–5030.
• Meritet J-F, Maury C, Tovey MG (2001) Induction of tolerance to recombinant therapeutic protein. J Interferon Cytokine Res 21: 1031–1038.
• Michalak M, Milner RE, Burns K, Opas M (1992) Calreticulin. Biochem J 285: 681–692.
• Michalak M, Corbett EF, Mesaeli N, Nakamura K, Opas M (1999) Calreticulin: one protein, one gene, many functions. Biochem J 344: 281–292.
• Mitrus I, Delić K, Wróbel N, Missol-Kolka E, Szala S (2006) Combination of IL-12 gene therapy and CTX chemotherapy inhibits growth of primary B16(F10) melanoma tumors in mice. Acta Biochim Polon 53: 357–360.
• Nyberg P, Xie L, Kalluri R (2005) Endogenous inhibitors of angiogenesis. Cancer Res 65: 3967–3979.
• O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277–285.
• O’Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J (1999) Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285: 1926–1928.
• Papetti M, Herman IM (2002) Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282: C947–C970.
• Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G (1998) Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 188: 2349–2356.
• Pike SE, Yao L, Setsuda J, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Atreya CD, Teruya-Feldstein , Wirth P, Gupta G, Tosato G (1999) Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 94: 2461–2468.
• Ribatti D, Vacca A (2005) Novel therapeutic approaches targeting vascular endothelial growth factor and its receptors in haematological malignancies. Curr Cancer Drug Targets 5: 573–578.
• Scappaticci FA (2002) Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20: 3906–3927.
• Schellekens H (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24: 1720–1740.
• Segers J, Fazio VD, Ansiaux R, Martinive P, Feron O, Wallemacq P, Gallez B (2006) Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the ‘normalization’ window of the tumor vasculature. Cancer Lett 244: 129–135.
• Sim BKL, O’Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA (1997) A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 57: 1329–1334.
• Wu Z, O’Reilly MS, Folkman J, Shing Y (1997) Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun 236: 651–654.
• Wu PC, Yang LC, Kuo HK, Huang CC, Tsai CL, Lin PR, Wu PC, Shin SJ, Tai MH (2005) Inhibition of corneal angiogenesis by local application of vasostatin. Mol Vis 11: 28–35.
• Yao L, Pike SE, Setsuda J, Parekh J, Gupta G, Raffeld M, Jaffe ES, Tosato G (2000) Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 96: 1900–1905.
• Yao L, Pike SE, Pittaluga S, Cherney B, Gupta G, Jaffe ES, Tosato G (2002a) Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Cancer Immunol Immunother 51: 358–366.
• Yao L, Pike SE, Tosato G (2002b) Laminin binding to the calreticulin fragment vasostatin regulates endothelial cell function. J Leukoc Biol 71: 47–53.